Track Panacea Life Sciences Holdings's EBIT ($-3.9M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
The latest EBIT for PLSH is $-3.9M as of June 2026. That compares with $5.2M in the prior-year period — down 175.1% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Panacea Life Sciences Holdings's historical trend and sector peers before judging valuation or financial health.
Over the past year, PLSH's EBIT moved from $5.2M to $-3.9M — a 175.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Panacea Life Sciences Holdings's operating scale or balance-sheet position.
Against its sector companies, PLSH currently prints $-3.9M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Panacea Life Sciences Holdings's growth, margins, and balance sheet.
A EBIT figure of $-3.9M for PLSH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.
After noting PLSH's EBIT ($-3.9M), review year-over-year change from $5.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.